News

Genervon Presents Future Goals for Investigational GM6 Therapy in Parkinson’s, Other Diseases

Genervon Biopharmaceuticals announced its future goals for investigational therapy GM6 in a recent presentation on its multi-target drug development strategy to tackle neurodegenerative diseases, including Parkinson’s disease. Genervon presented its hypothesis that a multi-target drug approach is the key to curing complex neurological disorders at the 2018 BIO CEO…

Excessive Calcium Levels in Brain May Play Role in Parkinson’s Disease

Excessive levels of calcium in the brain may trigger the formation of toxic protein clumps that typify Parkinson’s disease. This finding could be a new treatment target for researchers working to understand how and why people develop the neurodegenerative disease. The research, “C-terminal calcium binding of α-synuclein modulates synaptic vesicle…

Patient-on-a-Chip Program Could Benefit Parkinson’s Patients by Pinpointing Effective Treatment

A new personalized medical strategy that can replicate human biological systems in a small chip may help predict patients’ response to certain treatments based on their genetic makeup. Called Patient-on-a-Chip, the joint initiative by Cedars-Sinai and Emulate combines Cedars scientists’ expertise in stem cell technology with Emulate’s Human Emulation System,…